SciELO - Scientific Electronic Library Online

 
vol.35 issue4Evaluation of susceptibility and response to therapy with piperacillin-tazobactam in patients with infections caused by Escherichia coli with extended-spectrum β-lactamase (ESBL) CTX-MTemporal trend of hospital discharges due to infectious diseases in Chile, 2004-2014 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista chilena de infectología

Print version ISSN 0716-1018

Abstract

BARRAZA, Marlon et al. Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile. Rev. chil. infectol. [online]. 2018, vol.35, n.4, pp.351-357. ISSN 0716-1018.  http://dx.doi.org/10.4067/s0716-10182018000400351.

Background:

The increase of invasive fungal disease (IFD) in immunocompromised patients has led to the frequent prescription of highly active antifungal drugs but with a high economic cost.

Aim:

To characterize the use of antifungals drugs, evaluate its prescription and determine consumption and associated costs.

Methods:

Retrospective descriptive study from January 2015 to April 2016. Audit of prescriptions and review of clinical files. Each prescription was classified according to whether it corresponded to a possible, probable or proven invasive fungal disease (IFD). Consumptions and treatment costs were calculated.

Results:

152 antifungal prescriptions were audited in 79 patients. The total cost of antifungal medications was US $ 714,413. 52.1% of the expenditure (US $ 372,319) corresponded to indications in proven IFD, 10.7% (US $ 76,377) probable IFD, 0.8% (US $ 5,638) non-IFI, 12.2% (US $ 87,459) IFD possible and 1.5% (US $ 10,896) non-IFD and 22.6% (US $ 161,723) was prophylaxis. The highest consumption was in indications related to IFD tested with a proven DOT of 10.54 days, with liposomal amphotericin B and iv voriconazole the drugs with the highest consumption with a DOT probable_AnBL of 3.15 and DOT proven voriconazole iv of 3.01.

Conclusions:

The consumption of antifungal drug medications generates high costs at 12% of the total pharmacy budget of our institution. The expense was associated mainly with the indications in IFI tested the voriconazole and amphotericin B liposomal with the highest consumption which added to its high cost and prolonged days of general therapy a big impact in the budget.

Keywords : Antifungal drugs; antifungal stewardship; economic impact; invasive fungal diseases.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )